Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Naptumomab estafenatox |
Trade Name | |
Synonyms | ABR-217620 |
Drug Descriptions |
Naptumomab estafenatox (ABR-217620) is a chimeric protein with a T-cell-activating superantigen fused to the Fab of an antibody targeting the 5T4 tumor antigen, which may lead to T-cell activation and anti-tumor immune response (PMID: 24445502). |
DrugClasses | |
CAS Registry Number | 676258-98-3 |
NCIT ID | C95789 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Alpha 2 Interferon + Naptumomab estafenatox | Alpha 2 Interferon Naptumomab estafenatox | 0 | 0 |
Docetaxel + Naptumomab estafenatox | Docetaxel Naptumomab estafenatox | 0 | 0 |
Docetaxel + Naptumomab estafenatox + Obinutuzumab | Docetaxel Naptumomab estafenatox Obinutuzumab | 0 | 1 |
Naptumomab estafenatox | Naptumomab estafenatox | 0 | 0 |